Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2015
16th World Conference on Lung Cancer
Access to all presentations that occur during the 16th World Conference on Lung Cancer in Denver, Colorado
Presentation Date(s):- September 6 - 9, 2015
- Total Presentations: 2499
To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.
-
+
MTE 18 - Chemoprevention Trials: Past, Present, and Future (Ticketed Session)
- Type: Meet the Expert (Ticketed Session)
- Track: Prevention and Tobacco Control
- Presentations: 1
- Coordinates: 9/08/2015, 07:00 - 08:00, 108+110+112
-
+
MTE18.01 - Chemoprevention Trials: Past, Present, and Future
07:00 - 08:00 | Author(s): D. Wigle
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MTE 19 - Electronic Nicotine Delivery Devices (ENDS): eCigarettes (Ticketed Session)
- Type: Meet the Expert (Ticketed Session)
- Track: Prevention and Tobacco Control
- Presentations: 1
- Coordinates: 9/08/2015, 07:00 - 08:00, 702+704+706
-
+
MTE19.01 - Electronic Nicotine Delivery Devices (ENDS): eCigarettes
07:00 - 07:30 | Author(s): K.M. Cummings
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MTE 20 - Biology and Pathology of Neuroendocrine Cancers (Ticketed Session)
- Type: Meet the Expert (Ticketed Session)
- Track: Small Cell Lung Cancer
- Presentations: 2
- Coordinates: 9/08/2015, 07:00 - 08:00, 708+710+712
-
+
MTE20.01 - Biology and Pathology of Neuroendocrine Cancers
07:00 - 07:30 | Author(s): K. Kerr
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MTE20.02 - Biology and Pathology of Neuroendocrine Cancers: Small Cell Lung Cancer - Call for Action
07:30 - 08:00 | Author(s): I. Linnoila
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MTE 21 - Early Detection of Central Airway Lesions: Biology and Practical Clinical Approaches (Ticketed Session)
- Type: Meet the Expert (Ticketed Session)
- Track: Screening and Early Detection
- Presentations: 2
- Coordinates: 9/08/2015, 07:00 - 08:00, 703
-
+
MTE21.01 - Early Detection of Central Airway Lesions: Biology and Practical Clinical Approaches
07:00 - 07:30 | Author(s): A. McWilliams
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MTE21.02 - Biomarkers for Early Detection of Lung Cancer
07:30 - 08:00 | Author(s): G. Sozzi
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MTE 22 - Diagnosis and Treatment of MPM: Overview (Ticketed Session)
- Type: Meet the Expert (Ticketed Session)
- Track: Thymoma, Mesothelioma and Other Thoracic Malignancies
- Presentations: 1
- Coordinates: 9/08/2015, 07:00 - 08:00, 205+207
-
+
MTE22.01 - Diagnosis and Treatment of MPM: Overview
07:00 - 08:00 | Author(s): A. Scherpereel
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
PLEN 02 - Lung Cancer: IASLC Global Initiatives
- Type: Plenary
- Track: Plenary
- Presentations: 3
- Moderators:F.R. Hirsch
- Coordinates: 9/08/2015, 08:15 - 09:45, Plenary Hall (Bellco Theatre)
-
+
Introduction
08:15 - 08:20
- Abstract
No abstract available for this presentation
-
+
PLEN02.01 - 2015 WHO Classification of the Pathology and Genetics of Tumors of the Lung
08:20 - 09:00 | Author(s): W.D. Travis
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
PLEN02.02 - Revised (8th) Edition of TNM Staging System for Lung Cancer
09:00 - 09:40 | Author(s): R. Rami-Porta
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P2.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 102
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.01-001 - Dendritic Cells: Cytokine-Induced Killer Cells Therapy in Advanced Non-Small Cell Lung Cancer: A Case Report of an Aggressive Tumor Relapse
09:30 - 09:30 | Author(s): F.I.M. Heralde
- Abstract
Loading... -
+
P2.01-002 - Immunotherapy as an Effective Treatment Option in the Metastatic NSCLC in Spite of PD-1 or PDL-1 Inhibition and Line of Therapy
09:30 - 09:30 | Author(s): J. Corral
- Abstract
Loading... -
+
P2.01-003 - T-Cytotoxic Specific Immunotherapy in NSCLC with Brain Metastases NCT00104780
09:30 - 09:30 | Author(s): J. Nemunaitis
- Abstract
Loading... -
+
P2.01-004 - Oncologists' Comprehension and Beliefs Surrounding Cancer Immunotherapy in Advanced NSCLC
09:30 - 09:30 | Author(s): T. Herrmann
- Abstract
Loading... -
+
P2.01-005 - Relationship between Icotinib Exposure and Clinical Outcome in Chinese ANSCLC
09:30 - 09:30 | Author(s): L. Zhang
- Abstract
Loading... -
+
P2.01-006 - Continuing EGFR-TKI in Combination with Regional Chemotherapy Beyond RECIST PD for Patients with Advanced EGFR(+) Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): J. Zhang
- Abstract
Loading... -
+
P2.01-007 - Prognostic Factors including EGFR Status in Advanced Lung Adenocarcinoma Patients
09:30 - 09:30 | Author(s): S. Hayai
- Abstract
Loading... -
+
P2.01-008 - Efficacy and Tolerability Analysis of Icotinib in EGFR Mutation-Positive and Unknown Advanced NSCLC Patients from Eastern Coastal China
09:30 - 09:30 | Author(s): C. Zhang
- Abstract
Loading... -
+
P2.01-009 - EGFR Mutation and Brain Metastasis in Patients with Non Small Cell Lung Cancer
09:30 - 09:30 | Author(s): E.K. Cho
- Abstract
Loading... -
+
P2.01-010 - Early Radiographic Response to TKI in Non Small Cell Lung Cancer with EGFR Mutations
09:30 - 09:30 | Author(s): C. Salvador Coloma
- Abstract
Loading... -
+
P2.01-011 - Relationship between EGFR Mutation Status and Response to Specific Chemotherapeutic Agents in Patients with Stage IV Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): V. Ernani
- Abstract
Loading... -
+
P2.01-012 - Clinical Implications of Isolated Bone Failure without Systemic Disease Progression During EGFR-TKI Treatment
09:30 - 09:30 | Author(s): J.A. Hwang
- Abstract
Loading... -
+
P2.01-013 - Association of PK/PG with Toxicity of Gefitinib in Patients with Advanced NSCLC
09:30 - 09:30 | Author(s): T. Hirose
- Abstract
Loading... -
+
P2.01-014 - EGFR Tyrosine Kinase Inhibitor and Chemotherapy in EGFR Mutation-Positive Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): K. Nishino
- Abstract
Loading... -
+
P2.01-015 - The Management of Brain Metastases in Patients with EGFR Mutated Advanced Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): N. O'Rourke
- Abstract
Loading... -
+
P2.01-016 - BPI-7701, a Covalent Mutant-Selective EGFR Inhibitor, Inhibits the Growth of NSCLC Lines with EGFR Activating and T790M Resistance Mutations
09:30 - 09:30 | Author(s): V.L. Wilde
- Abstract
Loading... -
+
P2.01-017 - Genetic Variations in the EGFR Gene Predicts Outcome in Advanced NSCLC Patients Treated with Erlotinib
09:30 - 09:30 | Author(s): A. Winther Larsen
- Abstract
Loading... -
+
P2.01-018 - Baseline Lymphocyte-Monocyte Ratio Is a Prognostic Marker in EGFR Mutant NSCLC Patients Receiving First Line EGFR TKIs
09:30 - 09:30 | Author(s): Y. Chen
- Abstract
Loading... -
+
P2.01-019 - Effect of EGFR Mutation Status on Graded Prognostic Assessment for Non-Small Cell Lung Cancer and Brain Metastases
09:30 - 09:30 | Author(s): Y.Y. Soon
- Abstract
Loading... -
+
P2.01-020 - Clinical Differences of EGFR Mutations in Exon 19 and 21 in Clinical Course of Non-Small Cell Lung Cancer Patients
09:30 - 09:30 | Author(s): T.W. Jang
- Abstract
Loading... -
+
P2.01-021 - Non-Inferior Progression Free Survival in NSCLC Patients Sensitive to EGFR TKI Receiving Low Dose versus Regular Dose of Gefitinib or Erlotinib
09:30 - 09:30 | Author(s): H. Chen
- Abstract
Loading... -
+
P2.01-022 - BMI as Factor Predicting the Efficacy of Gefitinib in NSCLC with EGFR Mutation
09:30 - 09:30 | Author(s): S. Hongyan
- Abstract
Loading... -
+
P2.01-023 - Intercalated Therapy with Gemcitabine, Cisplatin and Erlotinib May Be Superior to TKI Alone for Patients with Advanced EGFR Mutated NSCLC
09:30 - 09:30 | Author(s): M. Zwitter
- Abstract
Loading... -
+
P2.01-024 - An ENSURE Extension Study to Evaluate 2nd Line Erlotinib and Gemcitabine/Cisplatin Cross-Over Treatment for EGFR-Mutant Chinese NSCLC Patients
09:30 - 09:30 | Author(s): Y. Wu
- Abstract
Loading... -
+
P2.01-025 - Crizotinib in Advanced ALK-Positive NSCLC - A Retrospective Multicenter Study in the Slovak Republic
09:30 - 09:30 | Author(s): P. Kasan
- Abstract
Loading... -
+
P2.01-026 - Proactive Management of Potential Gastrointestinal Adverse Reactions with Ceritinib in Patients with Advanced ALK+ NSCLC
09:30 - 09:30 | Author(s): E. Schaefer
- Abstract
Loading... -
+
P2.01-027 - Responses to Crizotinib in Six Lung Adenocarcinoma Patients of ALK IHC-Positive and FISH-Negative
09:30 - 09:30 | Author(s): D. Ma
- Abstract
Loading... -
+
P2.01-028 - Neoadjuvant Crizotinib and Surgical Resection of Two Stage IIIA Lung Adenocarcinomas with Anaplastic Lymphoma Kinase Gene Rearrangement
09:30 - 09:30 | Author(s): S. Li
- Abstract
Loading... -
+
P2.01-029 - Physician Decision-Making on Modifying or Discontinuing Crizotinib in ALK+ NSCLC: A Survey of US Physicians
09:30 - 09:30 | Author(s): A. Guerin
- Abstract
Loading... -
+
P2.01-030 - Challenging Diagnosis of Adenocarcinoma of the Lung Confirmed by Molecular Analysis: A Clinical Case
09:30 - 09:30 | Author(s): R. El-Maraghi
- Abstract
Loading... -
+
P2.01-031 - Characteristics of Squamous Cellular Carcinoma Patients In 'Colombian Coffee Zone'
09:30 - 09:30 | Author(s): J.A. Echeverri F
- Abstract
Loading... -
+
P2.01-032 - Patterns of Care in Long Term Survivors (> 3 Years) in Advanced NSCLC- Retrospective Analysis of 30 Patients from a Single Institute
09:30 - 09:30 | Author(s): I.S. Yengkhom
- Abstract
Loading... -
+
P2.01-033 - Patients with Advanced NSCLC Requiring Inpatient Oncology Consultation
09:30 - 09:30 | Author(s): J. Gotfrit
- Abstract
Loading... -
+
P2.01-034 - Predictive Factors of Brain Metastases Development in Non-Small Cells Lung Cancer
09:30 - 09:30 | Author(s): E.A. Richardet
- Abstract
Loading... -
+
P2.01-035 - The Survival Effect of Resection of Cranial Metastatic Lesions in Patients with Lung Cancer
09:30 - 09:30 | Author(s): A. Deligonul
- Abstract
Loading... -
+
P2.01-036 - Long Term Survival of Patients with Metastatic Adenocarcinoma of the Lung in the Era of Targeted Agents
09:30 - 09:30 | Author(s): D. Paul
- Abstract
Loading... -
+
P2.01-037 - Genomic Alterations of KRAS, EGFR, and ALK in Patients with Non-Small Cell Lung Cancer, Single Institution Experience
09:30 - 09:30 | Author(s): Y.C. Tan
- Abstract
Loading... -
+
P2.01-038 - Prognostic Factors for Brain Metastasis in Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): N. Duma
- Abstract
Loading... -
+
P2.01-039 - Clinicopathological Factors in Non-Small Cell Lung Cancer Patients with Bone Metastases
09:30 - 09:30 | Author(s): A. Ulas
- Abstract
Loading... -
+
P2.01-040 - Survival Gains From Systemic Therapy in Advanced Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities
09:30 - 09:30 | Author(s): J.A. Roth
- Abstract
Loading... -
+
P2.01-041 - MD Anderson Oncology Expert Advisor™ System (OEA™): A Cognitive Computing Recommendations Application (App) for Lung Cancer
09:30 - 09:30 | Author(s): G.R. Simon
- Abstract
Loading... -
+
P2.01-042 - Cost-Effectiveness of Afatinib vs. Erlotinib in the 1st-Line Treatment of Metastatic NSCLC Patients with EGFR Exon 19 Deletion Mutations
09:30 - 09:30 | Author(s): J. Graham
- Abstract
Loading... -
+
P2.01-043 - Lung Cancer Radiotherapy - Current Patterns of Practice in Australia and New Zealand
09:30 - 09:30 | Author(s): S.M. Islam
- Abstract
Loading... -
+
P2.01-044 - EGFR-TKIs as Second-Line Treatment of Patients with NSCLC with or without Activating EGFR Mutation as Assessed by Sensitive PNA Clamping Method
09:30 - 09:30 | Author(s): Y. Kim
- Abstract
Loading... -
+
P2.01-045 - Clinical Experience on Treatment of Advanced Lung Adenocarcinoma With Unknown EGFR Gene Status From a Tertiary Care Center in China
09:30 - 09:30 | Author(s): L.Y. Zheng
- Abstract
Loading... -
+
P2.01-046 - Making the Diagnosis of Cardiac Tamponade in Lung Cancer Patients
09:30 - 09:30 | Author(s): P. Ghatalia
- Abstract
Loading... -
+
P2.01-047 - Fibrobronchoscopic Cryorecanalization for Unresectable Secondary Malignant Tumors of the Trachea and Main Bronchi
09:30 - 09:30 | Author(s): Q. Ma
- Abstract
Loading... -
+
P2.01-048 - Real-Life 2-Year Therapeutic Strategies in the Management of Metastatic Non-Small-Cell Lung Cancers: The ESCAP Study
09:30 - 09:30 | Author(s): D. Debieuvre
- Abstract
Loading... -
+
P2.01-049 - Surgical Treatment Results of T4 Lung Cancer Invading Mediastinum
09:30 - 09:30 | Author(s): M. Tanahashi
- Abstract
Loading... -
+
P2.01-050 - Influence of Maintenance Therapy on Incidence of 2nd Line Therapy and OS in NSCLC IV
09:30 - 09:30 | Author(s): A.C. Lueers
- Abstract
Loading... -
+
P2.01-051 - Determinants of Sequential versus Concurrent Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer Patients
09:30 - 09:30 | Author(s): I. Walraven
- Abstract
Loading... -
+
P2.01-052 - Augmentation of NAD+ by NQO1 Activation Attenuates Cisplatin-Mediated Hearing Impairment
09:30 - 09:30 | Author(s): S. Yang
- Abstract
Loading... -
+
P2.01-053 - The Role of Systemic Therapy in Sarcomatoid Carcinoma of the Lung
09:30 - 09:30 | Author(s): N. Abdel Karim
- Abstract
Loading... -
+
P2.01-054 - Continuation Maintenance Therapy of Pemetrexed and Renal Toxicities
09:30 - 09:30 | Author(s): T. Yamaguchi
- Abstract
Loading... -
+
P2.01-055 - Prospective Study of UGT1A1*27 Gene Polymorphism for Irinotecan Therapy: Result of Lung Oncology Group in Kyushu (LOGiK1004B)
09:30 - 09:30 | Author(s): M. Fukuda
- Abstract
Loading... -
+
P2.01-056 - Thyroid Transcription Factor 1 (TTF1) as a Possible Predictive Biomarker for Pemetrexed-Based Chemotherapy in Non-Squamous NSCLC
09:30 - 09:30 | Author(s): X. Mielgo Rubio
- Abstract
Loading... -
+
P2.01-057 - Serum Mass-Spectrometry Test in First-Line Advanced Non-Small Cell Lung Cancer Patients Treated with Standard Chemotherapy Regimens
09:30 - 09:30 | Author(s): F. Grossi
- Abstract
Loading... -
+
P2.01-058 - Factors Predicting Long Duration of Pemetrexed Maintenance Therapy: A Retrospective Cohort of 65 Patients
09:30 - 09:30 | Author(s): C. Fontaine-Delaruelle
- Abstract
Loading... -
+
P2.01-059 - Does Pemetrexed/Platinum Fit All Patients with Non-Squamous Non-Small Cell Lung Cancer? A Retrospective Study of Clinical Factors and Outcomes
09:30 - 09:30 | Author(s): J. Shimizu
- Abstract
Loading... -
+
P2.01-060 - Biweekly Irinotecan/Bevacizumab in Heavily Treated Advanced NSCLC and Survival According to TIMP1 and EGFR Expression
09:30 - 09:30 | Author(s): A.F. Cardona
- Abstract
Loading... -
+
P2.01-061 - COX-2 Expression Does Not Predict Outcome of Celecoxib in Addition to Standard Chemotherapy in Advanced Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): M. Gulyás
- Abstract
Loading... -
+
P2.01-062 - Efficacy and Safety of Weekly Albumin-Bound Paclitaxel for Non-Small-Cell Lung Cancer Patients Who Have Failed ≥ 2 Prior Systemic Regimens
09:30 - 09:30 | Author(s): J. Wang
- Abstract
Loading... -
+
P2.01-063 - Dynamic Change of Fatigue for East-Asian Patients in the JMEN Trial
09:30 - 09:30 | Author(s): L. Zhang
- Abstract
Loading... -
+
P2.01-064 - A Randomized Phase II Trial of ERCC1 and RRM1 Expression-Based Chemotherapy versus Docetaxel/Carboplatin in Advanced Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): S.J. Heo
- Abstract
Loading... -
+
P2.01-065 - nab-Paclitaxel + Carboplatin in Advanced NSCLC: Analysis of Age and Renal Function
09:30 - 09:30 | Author(s): E. Bernicker
- Abstract
Loading... -
+
P2.01-066 - A Prospective, Randomized, Multicenter, Phase III Study, Comparing rhTPO with rhIL-11 Treating CIT - An Interim Analysis (NCT02344979)
09:30 - 09:30 | Author(s): S. Lu
- Abstract
Loading... -
+
P2.01-067 - Quality in Lung Cancer Care: The Victorian Lung Cancer Registry Pilot Initial Report
09:30 - 09:30 | Author(s): R. Stirling
- Abstract
Loading... -
+
P2.01-068 - Androgen Deprivation Therapy for Prostate Cancer Associated with Improved Survival in Non Small Cell Lung Cancer: A SEER-MEDICARE Analysis
09:30 - 09:30 | Author(s): M. Kumar
- Abstract
Loading... -
+
P2.01-069 - Design and Stratification for Phase III Trials in First-Line Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): T. Komiya
- Abstract
Loading... -
+
P2.01-070 - Serum Albumin in Patients with Advanced-Stage NSCLC Treated with Erlotinib
09:30 - 09:30 | Author(s): O. Fiala
- Abstract
Loading... -
+
P2.01-071 - TULUNG REGISTRY: Data Analysis of Patients with Non-Squamous NSCLC Treated with Bevacizumab in the Czech Republic
09:30 - 09:30 | Author(s): L. Havel
- Abstract
Loading... -
+
P2.01-072 - A Phase II Study of Carboplatin/Pemetrexed/Bevacizumab Followed by Bevacizumab/Erlotinib Maintenance for NonSq-NSCLC with Wild-Type EGFR
09:30 - 09:30 | Author(s): H. Yokouchi
- Abstract
Loading... -
+
P2.01-073 - Impact of Prophylactic Doxycycline (Doxy) on Maintaining Planned Dosing of Dacomitinib (D) an Irreversible panHER Inhibitor
09:30 - 09:30 | Author(s): M.E. Lacouture
- Abstract
Loading... -
+
P2.01-074 - Phase II Trial of Erlotinib Monotherapy for Pretreated Elderly Patients with Advanced EGFR Wild-Type Non-Small-Cell Lung Cancer
09:30 - 09:30 | Author(s): H. Minemura
- Abstract
Loading... -
+
P2.01-075 - Bevacizumab with Docetaxel or S-1 in Non-Squamous NSCLC (HANSHIN 0110)
09:30 - 09:30 | Author(s): M. Tachihara
- Abstract
Loading... -
+
P2.01-076 - Clinical Study of Anti-Angiogenesis Therapy Combined with Neo-Adjuvant Chemotherapy on NSCLC Patients in Phase IIIa (N2)
09:30 - 09:30 | Author(s): X. Zhao
- Abstract
Loading... -
+
P2.01-077 - A Phase 1b Trial of the Combination of Capecitabine and Erlotinib in Advanced Lung Cancer
09:30 - 09:30 | Author(s): R. Kumar
- Abstract
Loading... -
+
P2.01-078 - Concurrent Thoracic Radiotherapy and Tyrosine Kinase Inhibitors for Wild-Type EGFR Patients with Locally Advanced Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): Z.S. Zheng
- Abstract
Loading... -
+
P2.01-079 - A Phase I Study Comparing PF-06439535 (A Potential Biosimilar) with Bevacizumab
09:30 - 09:30 | Author(s): B. Knight
- Abstract
Loading... -
+
P2.01-080 - Pemetrexed, Carboplatin and Bevacizumab in Patients with Non-Squamous NSCLC without or with Activating EGFR Mutation (CJLSG0909/0910)
09:30 - 09:30 | Author(s): T. Kimura
- Abstract
Loading... -
+
P2.01-081 - Case Series of HER2 Mutated Metastatic Lung Adenocarcinoma and Response to HER2 Targeted Therapies
09:30 - 09:30 | Author(s): J. Chuang
- Abstract
Loading... -
+
P2.01-082 - Pathological Response with Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Use in Advanced Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): J. Hyder
- Abstract
Loading... -
+
P2.01-083 - Prognostic Significance of CK19mRNA Positive Cells in the Peripheral Blood of Patients with Advanced Non Small Cell Lung Cancer (NSCLC)
09:30 - 09:30 | Author(s): I. Messaritakis
- Abstract
Loading... -
+
P2.01-084 - Post-Market Clinical Trial of Dianhydrogalactitol in the Treatment of Relapsed or Refractory Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): A. Steino
- Abstract
Loading... -
+
P2.01-085 - Abemaciclib in Combination with Single Agent Options in Stage IV NSCLC, a Phase 1b Study
09:30 - 09:30 | Author(s): K. Kelly
- Abstract
Loading... -
+
P2.01-086 - Ceritinib in ALK+ NSCLC Metastatic to Brain and/or Leptomeninges: The ASCEND-7 Study
09:30 - 09:30 | Author(s): L.Q. Chow
- Abstract
Loading... -
+
P2.01-087 - A Phase 1 Trial Combining Plinabulin and Nivolumab for Metastatic Squamous NSCLC
09:30 - 09:30 | Author(s): S. Yeh
- Abstract
Loading... -
+
P2.01-088 - nab-Paclitaxel + Carboplatin for Elderly Patients with Advanced NSCLC (ABOUND.70+)
09:30 - 09:30 | Author(s): C.J. Langer
- Abstract
Loading... -
+
P2.01-089 - A Phase 1b/2 Randomized Study of PEGPH20 in Combination with Docetaxel in Hyaluronan High NSCLC Patients Treated with Platinum Chemotherapy
09:30 - 09:30 | Author(s): C.P. Belani
- Abstract
Loading... -
+
P2.01-090 - A Phase 2, Single Arm Study of Lucitanib in Patients with Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF-Related Genetic Changes
09:30 - 09:30 | Author(s): D.R. Spigel
- Abstract
Loading... -
+
P2.01-091 - Multicenter, Randomized, Double-Blind Study of Erlotinib plus Ramucirumab or Placebo in Patients with EGFR Mutation-Positive Metastatic NSCLC
09:30 - 09:30 | Author(s): E.B. Garon
- Abstract
Loading... -
+
P2.01-092 - A Phase IB Dose-Escalation Study of Pemetrexed and AUY922 in Previously Treated Metastatic Non-Squamous, Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): E.B. Garon
- Abstract
Loading... -
+
P2.01-093 - A Phase III Study of Radiosurgery with TTFields for 1-10 Brain Metastases from NSCLC
09:30 - 09:30 | Author(s): M.P. Mehta
- Abstract
Loading... -
+
P2.01-094 - Phase II Trial of Tepotinib/Gefitinib vs Cisplatin/Pemetrexed in T790M-/c-Met+ NSCLC
09:30 - 09:30 | Author(s): Y. Wu
- Abstract
Loading... -
+
P2.01-095 - nab-Paclitaxel/Carboplatin Followed By nab-Paclitaxel for NSCLC PS 2 (ABOUND.PS2)
09:30 - 09:30 | Author(s): A. Gajra
- Abstract
Loading... -
+
P2.01-096 - Randomized, Double-Blind, Placebo-Controlled Trial of Evofosfamide (TH-302) in Combination with Pemetrexed in Advanced ns-NSCLC
09:30 - 09:30 | Author(s): J.W. Goldman
- Abstract
Loading... -
+
P2.01-097 - Phase 3 Study of Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ NSCLC
09:30 - 09:30 | Author(s): T. Mok
- Abstract
Loading... -
+
P2.01-098 - Addition of Custirsen, a Clusterin Inhibitor, to Docetaxel in Stage IV Non-Small Cell Lung Cancer (NSCLC): The ENSPIRIT™ Phase 3 Trial
09:30 - 09:30 | Author(s): J. Von Pawel
- Abstract
Loading... -
+
P2.01-099 - nab-Paclitaxel as Maintenance Therapy in Patients with Squamous Cell NSCLC (ABOUND.sqm)
09:30 - 09:30 | Author(s): D.R. Spigel
- Abstract
Loading... -
+
P2.01-100 - Phase Ib Trial of Afatinib and BI 836845 in Advanced Non-Small Cell Lung Cancer (NSCLC)
09:30 - 09:30 | Author(s): K. Park
- Abstract
Loading... -
+
P2.01-101 - Randomized Phase 3 Trial of Docetaxel+Plinabulin Compared to Docetaxel in Advanced Non-Small Cell Lung Cancer with at Least 1 Large Lung Lesion
09:30 - 09:30 | Author(s): L. Bazhenova
- Abstract
Loading... -
+
P2.01-102 - Phase I Study of Inhaled 5-Azacytidine in Patients with Advanced NSCLC
09:30 - 09:30 | Author(s): E. Yilmaz
- Abstract
Loading...
-
+
P2.02 - Poster Session/ Treatment of Localized Disease – NSCLC
- Type: Poster
- Track: Treatment of Localized Disease - NSCLC
- Presentations: 41
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.02-001 - Predictors of Occult Nodal Metastasis in Clinical Stage I NSCLC Staged by FDG-PET/CT
09:30 - 09:30 | Author(s): K. Kaseda
- Abstract
Loading... -
+
P2.02-002 - Impact of Multiple Cancer Treatment History on Outcome in Patients with Surgically Resected Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): M. Anraku
- Abstract
Loading... -
+
P2.02-003 - Blood Loss Volume During Surgery Is a Significant Adverse Prognostic Factor in Patients with Stage I to IIIA Resected NSCLC
09:30 - 09:30 | Author(s): W. Liang
- Abstract
Loading... -
+
P2.02-004 - Clinicopathological Features and Outcomes of AAH, AIS and MIA in Resected Lung Adenocarcinoma
09:30 - 09:30 | Author(s): H. Ishida
- Abstract
Loading... -
+
P2.02-005 - Precise Prediction of 5-Year Survival of Lung Cancer Patients after Radical Surgery
09:30 - 09:30 | Author(s): O. Kshivets
- Abstract
Loading... -
+
P2.02-006 - Development of the New Photodynamic Therapy for Peripheral Type Lung Cancer
09:30 - 09:30 | Author(s): K. Ohtani
- Abstract
Loading... -
+
P2.02-007 - Correlation Between Histological Invasiveness and CT Value in Pure GGNs
09:30 - 09:30 | Author(s): A. Kitami
- Abstract
Loading... -
+
P2.02-008 - Planning the Optimal Patient Pathway in the Diagnosis and Staging of Suspected Lung Cancer; What Infrastructure Is Needed?
09:30 - 09:30 | Author(s): M. Evison
- Abstract
Loading... -
+
P2.02-009 - Expected Variability of C-Reactive Protein after Pulmonary Resections: Which Factors Are Associated with Their Normal Variation?
09:30 - 09:30 | Author(s): D.G. Augusto
- Abstract
Loading... -
+
P2.02-010 - Pathological Examination of Primary Lung Adenocarcinoma Cases That Were Positive for Intraoperative Pleural Effusion (E1(+), M1a)
09:30 - 09:30 | Author(s): M. Shimomura
- Abstract
Loading... -
+
P2.02-011 - Optimal Strategy to Prevent Atrial Fibrillation in Patients Undergoing Pulmonary Resection for Lung Cancer. Network Meta-Analysis
09:30 - 09:30 | Author(s): M. Kowalewski
- Abstract
Loading... -
+
P2.02-012 - Prediction of Postoperative Pulmonary Function Using CT Volumetry
09:30 - 09:30 | Author(s): M. Hashimoto
- Abstract
Loading... -
+
P2.02-013 - Strategy of Management for Synchronous Pure GGOs Detected in Patients Undergoing Resection for Primary NSCLC
09:30 - 09:30 | Author(s): C. Dai
- Abstract
Loading... -
+
P2.02-014 - Cross-Sectional Study on Surgical Treatment Patterns of 1927 Stage I-IIIa NSCLC Patients from 11 Medical Centers in China in 2013
09:30 - 09:30 | Author(s): J. Zhou
- Abstract
Loading... -
+
P2.02-015 - Prognostic Significance of Histologic Subtype in Stage I Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): Y. Moon
- Abstract
Loading... -
+
P2.02-016 - A New Strategy for Preoperative-Management of Patients with Lung Cancer with Chronic Obstructive Pulmonary Disease (COPD)
09:30 - 09:30 | Author(s): J. Usuda
- Abstract
Loading... -
+
P2.02-017 - Video-Assisted Mediastinoscopic Lymphadenectomy Decreases the Need for Lymph Node Dissection during Lobectomy in Lung Cancer Patients
09:30 - 09:30 | Author(s): A. Turna
- Abstract
Loading... -
+
P2.02-018 - Evaluation of Invasiveness among 3 Methods of Thoracoscopic Lobectomy in Patients with NSCLC: A Favorable Result for Uniportal VATS
09:30 - 09:30 | Author(s): Q. Zhu
- Abstract
Loading... -
+
P2.02-019 - Role of Sentinel Node Biopsy in Stage IA NSCLC Surgery
09:30 - 09:30 | Author(s): N. Ilic
- Abstract
Loading... -
+
P2.02-020 - Determining the Location of Early-Stage Lung Cancer Using an Endoscopic Ultrasound Device during VATS Procedure
09:30 - 09:30 | Author(s): T. Inoue
- Abstract
Loading... -
+
P2.02-021 - Robotic Pulmonary Resection for Lung Cancer: Analysis of the Learning Curve in a Novel Surgical Program
09:30 - 09:30 | Author(s): W.C. Hanna
- Abstract
Loading... -
+
P2.02-022 - Short and Long-Term Outcomes of Pneumonectomy for Lung Cancer: 15-Years Experience
09:30 - 09:30 | Author(s): S.S.A. Qadri
- Abstract
Loading... -
+
P2.02-023 - Robotic Thoracic Surgery for Elderly Patients with Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): R.T. Hughes
- Abstract
Loading... -
+
P2.02-024 - Simplified Comorbidity Score for Elderly Patients with Primary Lung Cancer Treated by Video-Assisted Thoracoscopic Surgery
09:30 - 09:30 | Author(s): Y. Yurugi
- Abstract
Loading... -
+
P2.02-025 - The Equivalent Efficacy of Multiple Operations for MPLC and a Single Operation for SPLC
09:30 - 09:30 | Author(s): K. Chen
- Abstract
Loading... -
+
P2.02-026 - Mediastainal Lymph Node Metasatsis Pattern from Left Upper Lobe Cancer: Results of Bilateral Superior Mediastinal Nodal Dissection
09:30 - 09:30 | Author(s): T. Yokota
- Abstract
Loading... -
+
P2.02-027 - A Study of Segmentectomy for Primary Lung Cancer
09:30 - 09:30 | Author(s): K. Mizuno
- Abstract
Loading... -
+
P2.02-028 - Diagnostic and Therapeutic Benefits of Thoracoscopic Surgery in Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma
09:30 - 09:30 | Author(s): H. Kato
- Abstract
Loading... -
+
P2.02-029 - Pre-Operative Pulmonary Function Tests (PFT) and Outcomes from Stage I and II Non-Small Cell Lung Cancer (NSCLC) Treated with Surgery
09:30 - 09:30 | Author(s): N. Khanal
- Abstract
Loading... -
+
P2.02-030 - Bronchoscopic Therapy for Centrally-Located Early Lung Cancers
09:30 - 09:30 | Author(s): T. Ishizumi
- Abstract
Loading... -
+
P2.02-031 - Surgical Management of Bronchial Carcinoid Tumors: A Monocentric Tunisian Experience
09:30 - 09:30 | Author(s): T. Kilani
- Abstract
Loading... -
+
P2.02-032 - Phase II Clinical Trial of Stereotactic Ablative Radiotherapy (SABR) in Surgically Operable Stage I Non-Small Cell Lung Cancer (STARS)
09:30 - 09:30 | Author(s): J.Y. Chang
- Abstract
Loading... -
+
P2.02-033 - Actual Situation of Adjuvant Chemotherapy for NSCLC in Japan
09:30 - 09:30 | Author(s): R. Nakajima
- Abstract
Loading... -
+
P2.02-034 - Induction Therapy with Intercalated TKI and Chemotherapy in NSCLC with Activating EGFR Mutation in Stages II-IIIB: NeoIntercal
09:30 - 09:30 | Author(s): F. Griesinger
- Abstract
Loading... -
+
P2.02-035 - Is There an Optimal Time to Initiate Adjuvant Chemotherapy in Order to Predict the Benefit of Survival in Non-Small Cell Lung Cancer?
09:30 - 09:30 | Author(s): X. Zhai
- Abstract
Loading... -
+
P2.02-036 - Radiation Therapy Alone in cT1-3N0 Lung Cancer Patients Who Are Unfit for Surgery or Stereotactic Ablative Radiation Therapy
09:30 - 09:30 | Author(s): Y.C. Ahn
- Abstract
Loading... -
+
P2.02-037 - Evaluation of the Dosimetric Characteristics of Salvage Lung SBRT with Image Deformable Registration Technique
09:30 - 09:30 | Author(s): K. Li
- Abstract
Loading... -
+
P2.02-038 - Clinical Evaluations of Odd/Even Respiratory Phases Based Approach for Determining Internal Target Volume in NSCLC Treated with 4D SABR
09:30 - 09:30 | Author(s): X.D. Li
- Abstract
Loading... -
+
P2.02-039 - Patterns-Of-Care Study of Stereotactic Ablative Radiotherapy for Lung Cancer in Korea
09:30 - 09:30 | Author(s): S. Song
- Abstract
Loading... -
+
P2.02-040 - Clinical Outcome of Fiducial-Less CyberKnife Stereotactic Ablative Body Radiotherapy for Stage I Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): I. Jung
- Abstract
Loading... -
+
P2.02-041 - Stereotactic Body Radiotherapy (SBRT) or Surgery in Early Stage (I & II) Non Small Cell Lung Cancer (NSCLC)
09:30 - 09:30 | Author(s): H. Koyi
- Abstract
Loading...
-
+
P2.03 - Poster Session/ Treatment of Locoregional Disease – NSCLC
- Type: Poster
- Track: Treatment of Locoregional Disease – NSCLC
- Presentations: 38
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.03-001 - Perioperative Cardiac Events in Patients with Coronary Artery Stent Undergoing Lung Resection for Lung Cancer
09:30 - 09:30 | Author(s): T. Ibi
- Abstract
Loading... -
+
P2.03-002 - Surgery for Locally Advanced Lung Cancer after Induction Concurrent Chemo-Radiation Therapy
09:30 - 09:30 | Author(s): K. Okabe
- Abstract
Loading... -
+
P2.03-003 - Video Assisted Thoracoscopic Anatomical Resection for Non Small Cell Lung Cancer (NSCLC) Is Increasingly Safe
09:30 - 09:30 | Author(s): D.M. Avella
- Abstract
Loading... -
+
P2.03-004 - Surgical Outcomes of Locally Advanced Non-Small Cell Lung Cancer Invading Great Vessels and Heart
09:30 - 09:30 | Author(s): B. Park
- Abstract
Loading... -
+
P2.03-005 - Surgical Resection after Definitive Chemoradiotherapy
09:30 - 09:30 | Author(s): L. Romero Vielva
- Abstract
Loading... -
+
P2.03-006 - Survival Rates after Surgery for Stage-3A (N2) Non-Small Cell Lung Cancer with Induction versus Adjuvant Chemotherapy+/-Radiation Therapy
09:30 - 09:30 | Author(s): E.M. Toloza
- Abstract
Loading... -
+
P2.03-007 - Pneumonectomy for Non Small Cell Lung Carcinoma: Pre-Operative Comorbidities and Post-Operative Morbidity Affect Long Term Survival
09:30 - 09:30 | Author(s): M.A. Vandeusen
- Abstract
Loading... -
+
P2.03-008 - Surgery for Primary Lung Tumors with Histology Other than Non-Small Cell Lung Cancer: A Single Center Experience
09:30 - 09:30 | Author(s): D. Pandey
- Abstract
Loading... -
+
P2.03-009 - Single Institutional Experience of the Surgical Treatment of Second Primary Lung Cancer
09:30 - 09:30 | Author(s): H. Saji
- Abstract
Loading... -
+
P2.03-010 - Sleeve, Semsleeve Lobectomy, Segment Pyramidobasalectomy in Patients with Preoperative Contraindication for Pneumonectomy
09:30 - 09:30 | Author(s): F. Gradica
- Abstract
Loading... -
+
P2.03-011 - A Phase II Trial of Concurrent Chemoradiation with Consolidation Pembrolizumab in Unresectable Stage III Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): G. Durm
- Abstract
Loading... -
+
P2.03-012 - Neoadjuvant Chemoradiotherapy or Chemotherapy Followed by Surgery Is Superior to That Definitive Chemoradiation in Stage IIIA (N2) NSCLC
09:30 - 09:30 | Author(s): X. Xu
- Abstract
Loading... -
+
P2.03-013 - A Phase II Study of S-1 and Thoracic Irradiation for Elderly Pts with Locally Advanced Non-Small Cell Lung Cancer: Okayama Lung Cancer Study Group
09:30 - 09:30 | Author(s): H. Ueoka
- Abstract
Loading... -
+
P2.03-014 - Correlation of Response and Prognostic Markers with Survival in Locally Advanced NSCLC Patients Who Have Treated with Neoadjuvant Chemotherapy
09:30 - 09:30 | Author(s): O. Altundag
- Abstract
Loading... -
+
P2.03-015 - A Phase II Trial of Individual Trimodality Treatment in Patients with Stage IIIA (N2) Non-Small Cell Lung Cancer: The ZTOG 1202 Study
09:30 - 09:30 | Author(s): Y. Xu
- Abstract
Loading... -
+
P2.03-016 - Comparing Outcomes of Neoadjuvant and Adjuvant Chemotherapy in Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): S. Sharma
- Abstract
Loading... -
+
P2.03-017 - Pre-Operative Chemotherapy Followed by Surgery for N2 Non-Small Cell Lung Cancer: A 15-Year Experience
09:30 - 09:30 | Author(s): J.D. Spicer
- Abstract
Loading... -
+
P2.03-018 - Tolerability of Re-Irradiation for Locally Recurrent Lung Cancer
09:30 - 09:30 | Author(s): V. Finnegan
- Abstract
Loading... -
+
P2.03-019 - A Phase II Multicentre Study of Gefitinib in Combination with Irradiation Followed by Chemotherapy in Patients with Inoperable Stage III NSCLC
09:30 - 09:30 | Author(s): A. Levy
- Abstract
Loading... -
+
P2.03-020 - Radical Lung Resection after Curative Chemoradiotherapy for Locally Advanced Lung Cancer
09:30 - 09:30 | Author(s): M. Yamashita
- Abstract
Loading... -
+
P2.03-021 - Impact of Radiation on Recurrence Patterns and Survival for Patients Undergoing Lobectomy for Stage IIIA-pN2 Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): C.J. Yang
- Abstract
Loading... -
+
P2.03-022 - Is the Radiosensitivity of the Tumour Related to That of the Lung? A CT-Based Response Analysis of Both
09:30 - 09:30 | Author(s): G. Defraene
- Abstract
Loading... -
+
P2.03-023 - In-Field Nodal Relapse after Irradiation for Locally Advanced Non-Small-Cell Lung Cancer: Is There a Dose-Effect Relationship?
09:30 - 09:30 | Author(s): L. Van Den Bosch
- Abstract
Loading... -
+
P2.03-024 - PORT-First Strategy After Surgery in Patients with IIIA-N2 Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): H.W. Lee
- Abstract
Loading... -
+
P2.03-025 - Predictors of Relapse and Evaluation of Post-Operative Radiotherapy in Patients with Resected Stage III (N2) Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): W. Breen
- Abstract
Loading... -
+
P2.03-026 - Assessing the Risk of Cardiac Toxicity with Esophageal-Sparing Intensity Modulated Radiotherapy for Locally Advanced Lung Cancers
09:30 - 09:30 | Author(s): K. Woodford
- Abstract
Loading... -
+
P2.03-027 - Predicting the Effect of 7-Days-A-Week Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer Based on Clinicopathological Features
09:30 - 09:30 | Author(s): R. Suwinski
- Abstract
Loading... -
+
P2.03-028 - Functional Lung Imaging with Perfusion SPECT/CT Improves Prediction of Radiation Pneumonitis
09:30 - 09:30 | Author(s): J. Zeng
- Abstract
Loading... -
+
P2.03-029 - SBRT for Localized Central NSCLC Conventional Radiation Failures; Recurrent Laryngeal Nerve Paralysis Is a Novel Toxicity
09:30 - 09:30 | Author(s): R. Malik
- Abstract
Loading... -
+
P2.03-030 - Adjuvant Radiation Therapy Improves Survival in Pathological Stage IIIA N2 Non-Small Cell Lung Cancer Patients Staged with PET
09:30 - 09:30 | Author(s): M.M. Tin
- Abstract
Loading... -
+
P2.03-031 - Subgroup Analysis of East Asian Patients in the Phase III PROCLAIM Trial
09:30 - 09:30 | Author(s): L.(. Wang
- Abstract
Loading... -
+
P2.03-032 - Prognostic Impact of EGFR and KRAS Mutations in Patients with Lung Adenocarcinoma Treated with Definitive Radiation Therapy
09:30 - 09:30 | Author(s): F. Oro
- Abstract
Loading... -
+
P2.03-033 - 18FDG-PET/CT Improves Lung Cancer Staging and Treatment Selection Accuracy
09:30 - 09:30 | Author(s): M. Majem
- Abstract
Loading... -
+
P2.03-034 - Association of EGFR Mutation Status with Treatment Outcome in Stage III Non-small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy
09:30 - 09:30 | Author(s): S.F. Nyaw
- Abstract
Loading... -
+
P2.03-035 - Impact of Lymph Node Involvement on Survival in Patients with Completely Resected Pulmonary Squamous Cell Carcinoma
09:30 - 09:30 | Author(s): Y. Kudo
- Abstract
Loading... -
+
P2.03-036 - Primary Pulmonary Large Cell Carcinoma with Syncytiotrophoblastic Aspect: Report of a Case
09:30 - 09:30 | Author(s): L. Ventura
- Abstract
Loading... -
+
P2.03-037 - Prognostic Factors in Pathologic N2 Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): H. Kim
- Abstract
Loading... -
+
P2.03-038 - Whole Tumor Perfusion CT in Patients with NSCLC Treated with Endostar Combined with Concurrent Radiotherapy
09:30 - 09:30 | Author(s): L. Shi
- Abstract
Loading...
-
+
P2.04 - Poster Session/ Biology, Pathology, and Molecular Testing
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 109
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.04-001 - EGFR Activating and T790M Resistance Mutation in Plasma exoRNA and cfDNA, Detected with Single-Step Isolation Columns and Targeted Resequencing
09:30 - 09:30 | Author(s): D. Enderle
- Abstract
Loading... -
+
P2.04-002 - Q787Q EGFR Polymorphism as a Prognostic Factor for Lung Squamous Cell Carcinoma
09:30 - 09:30 | Author(s): Y.W. Koh
- Abstract
Loading... -
+
P2.04-003 - Two Methods for Developing in Vitro Erlotinib-Resistant Cell Lines Lead to Distinct RTK Shifts, but Both Result in EMT
09:30 - 09:30 | Author(s): K.R. Jakobsen
- Abstract
Loading... -
+
P2.04-004 - The BIM Deletion Polymorphism in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors
09:30 - 09:30 | Author(s): J.Y. Lee
- Abstract
Loading... -
+
P2.04-005 - Bevacizumab plus Erlotinib in B901L Xenograft Model of EGFR Mut+ NSCLC
09:30 - 09:30 | Author(s): C. Masuda
- Abstract
Loading... -
+
P2.04-006 - MiRNA Signature to Assess Sensitivity to FGFR Tyrosine Kinase Inhibitors
09:30 - 09:30 | Author(s): C.J. Rivard
- Abstract
Loading... -
+
P2.04-007 - In Vitro and in Vivo Efficacy of AZD9291 Is Enhanced by Combination with AZD4547 in EGFR Mutant Lung Cancer Cells
09:30 - 09:30 | Author(s): D.C. Chan
- Abstract
Loading... -
+
P2.04-008 - IGF1R Expression Is Predictive of Poor Prognosis in EGFR-Mutant Lung Adenocarcinoma
09:30 - 09:30 | Author(s): E. Park
- Abstract
Loading... -
+
P2.04-009 - Potential Predictive Markers with Plasma for Re-Challenge with EGFR-TKIs
09:30 - 09:30 | Author(s): T. Nakamura
- Abstract
Loading... -
+
P2.04-010 - 18F-FDG Uptake and CEA between Different EGFR Mutations in Patients with Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): X. Dong
- Abstract
Loading... -
+
P2.04-011 - Whole-Genome Copy Number Analyses of NSCLC Tumors Reveal Aberrations Associated With EGFR Mutations and May Have Prognostic Impact
09:30 - 09:30 | Author(s): M.M. Bjaanæs
- Abstract
Loading... -
+
P2.04-012 - The Development of EGFR Mutation Diagnostic Program for NSCLC Patients in Poland (2011-2014)
09:30 - 09:30 | Author(s): J. Chorostowska-Wynimko
- Abstract
Loading... -
+
P2.04-013 - TraiL Mediates Erlotinib-Induced Apoptosis in EGFR-Mutant Lung Cancer 3D Spheroids
09:30 - 09:30 | Author(s): H. Lee
- Abstract
Loading... -
+
P2.04-014 - High Resolution Metabolomics to Discover the Potential Biomarkers in EGFR Mutated Lung Cancer
09:30 - 09:30 | Author(s): J.W. Lee
- Abstract
Loading... -
+
P2.04-015 - Screening EGFR Mutations in NSCLC by Immunohistochemistry
09:30 - 09:30 | Author(s): R. Gaber
- Abstract
Loading... -
+
P2.04-016 - Minority Exon 19 Deletions Also Have Major Response of EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): E. Nakajima
- Abstract
Loading... -
+
P2.04-017 - The Study of a Relationship between Thyroid Transcription Factor-1 Expression and EGFR Mutations in Unselected Thai Patients with NSCLC
09:30 - 09:30 | Author(s): C. Charoentum
- Abstract
Loading... -
+
P2.04-018 - Whole Transcriptome Analysis of EGFR Wildtype Non-Small Cell Lung Cancer Patients with Clinical Benefit from Erlotinib
09:30 - 09:30 | Author(s): M.F. Sharpnack
- Abstract
Loading... -
+
P2.04-019 - PD 0332991 Inhibits the Growth of Gefitinib-Resistant Human Lung Cancer Cells in Vitro and in Vivo, When Combined with Gefitinib
09:30 - 09:30 | Author(s): H. Liu
- Abstract
Loading... -
+
P2.04-020 - Epidermal Growth Factor Receptor (EGFR) Testing among Veterans Diagnosed with Lung Cancer
09:30 - 09:30 | Author(s): J. Lynch
- Abstract
Loading... -
+
P2.04-021 - Predictive Value of Initial Maximal Standardized Uptake Value of 18F-FDG PET/CT in Patients with Lung Adenocarcinoma Treated with Erlotinib
09:30 - 09:30 | Author(s): T. Kus
- Abstract
Loading... -
+
P2.04-022 - Development of Microfluidic Devices for Rapid, Low-Cost Detection of EGFR Mutations in Cytological Samples from Patients with Lung Cancer
09:30 - 09:30 | Author(s): T. Hase
- Abstract
Loading... -
+
P2.04-023 - Global Epidemiology of EGFR Mutation in Advanced Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): G. Werutsky
- Abstract
Loading... -
+
P2.04-024 - NGS reveals potential druggable targets and molecular heterogeneity in EGFR mutant NSCLC with acquired resistance to EGFR TKIs
09:30 - 09:30 | Author(s): C. Lee
- Abstract
Loading... -
+
P2.04-025 - Frequency of EGFR Mutation in Nsclc and Its Relationship with Clinicopathological Features: A Multicenter Asmo Trial
09:30 - 09:30 | Author(s): S. Yuksel
- Abstract
Loading... -
+
P2.04-026 - Second Generation EGFR TKIs Inhibit Tumor Growth in a Chemo-Resistant Squamous Cell Lung Cancer Patient Derived Xenograft Model
09:30 - 09:30 | Author(s): C. Mascaux
- Abstract
Loading... -
+
P2.04-027 - Erlotinib Induce miRNA Alterations in T790M EGFR Mutated NSCLC: Preclinical Study
09:30 - 09:30 | Author(s): J. Chacartegui
- Abstract
Loading... -
+
P2.04-028 - BIM Deletion Polymorphisms in Hispanic Patients with Non-Small Cell Lung Cancer Who Carriers EGFR Mutations (CLICaP)
09:30 - 09:30 | Author(s): A.F. Cardona
- Abstract
Loading... -
+
P2.04-029 - Could EGFR Gene Mutations Provide a Selective Advantage to Malignant Cells in Specific Sites? New Perspectives in Lung Adenocarcinoma Biology
09:30 - 09:30 | Author(s): T. Franchina
- Abstract
Loading... -
+
P2.04-030 - Activating and Resistance Mutations of EGFR in Peruvian Patients with Metastatic NSCLC
09:30 - 09:30 | Author(s): J.C. Gomez De La Torre
- Abstract
Loading... -
+
P2.04-031 - EGFR Mutation Associated with Histologic Subtype According to the IASLC/ATS/ERS Adenocarcinoma Classification: A Meta-Analysis
09:30 - 09:30 | Author(s): C.H. Ma
- Abstract
Loading... -
+
P2.04-032 - Epidemiology and Clinical Outcomes of Epidermal Growth Factor Receptor (EGFR) Mutant Patients at the Brazilian National Cancer Institute (INCA)
09:30 - 09:30 | Author(s): P.M. Domingues
- Abstract
Loading... -
+
P2.04-033 - Patterns of EGFR Mutations in a Cohort of 395 Patients from a Single Institution in Brazil
09:30 - 09:30 | Author(s): A.O. Saito
- Abstract
Loading... -
+
P2.04-034 - The Study of EGFR Mutation Specific-Antibody for Detection of EGFR Status in Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): C. Charoentum
- Abstract
Loading... -
+
P2.04-035 - Methods for Evaluating Early Response to Erlotinib Treatment Using FDG-PET/CT
09:30 - 09:30 | Author(s): J. Fledelius
- Abstract
Loading... -
+
P2.04-036 - The Association of EGFR Mutations with Stage at Diagnosis in Lung Adenocarcinomas
09:30 - 09:30 | Author(s): J. Cho
- Abstract
Loading... -
+
P2.04-037 - Frequency of EGFR Mutations in NSCLC Patients of the Lung Center of the Philippines
09:30 - 09:30 | Author(s): M.T.A. Barzaga
- Abstract
Loading... -
+
P2.04-038 - EGFR Mutation Prevalence and Epidemiological Profile of Patients with Metastatic Nonsquamous Non Small Cell Lung Cancer
09:30 - 09:30 | Author(s): M.F.E. Simões
- Abstract
Loading... -
+
P2.04-039 - A World of EGFR Screening Test
09:30 - 09:30 | Author(s): M. Carbonnaux
- Abstract
Loading... -
+
P2.04-040 - Impact of Ethnicity on Incidence of Brain Metastasis in Patients with EGFR-Mutant Lung Cancer
09:30 - 09:30 | Author(s): J. Zhang
- Abstract
Loading... -
+
P2.04-041 - Characterization of EGFR Activating Mutations in Brazilian Patients with Pulmonary Adenocarcinoma
09:30 - 09:30 | Author(s): C.T. Yen
- Abstract
Loading... -
+
P2.04-042 - Mutation of Epidermal Growth Factor Receptor (EGFR) in Patients with Non-Small Cell Lung Cancer (NSCLC) in a University Hospital in Latin America
09:30 - 09:30 | Author(s): L.F. Sua
- Abstract
Loading... -
+
P2.04-043 - A Successful Case in Which Electromagnetic Navigation Bronchoscopy Identified an EGFR Mutation in Small Peripheral Lung Lesions
09:30 - 09:30 | Author(s): J. Singh
- Abstract
Loading... -
+
P2.04-044 - Analysis of the Intra-Tumor Heterogeneity and Consistency between FGFR1 Gene Amplification and Protein Expression in Squamous Cell Lung Cancer
09:30 - 09:30 | Author(s): M.M. Skupinska
- Abstract
Loading... -
+
P2.04-045 - Targeting eIF4A1 and eIF4A2 mRNA Helicases in Pulmonary Adenocarcinoma
09:30 - 09:30 | Author(s): F. Raza
- Abstract
Loading... -
+
P2.04-046 - Kinome RNAi Screens Identify Essential Genes and Therapeutics In 'Driver Negative' Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): J. Kim
- Abstract
Loading... -
+
P2.04-047 - Mitochondrial Activation- A Potential Therapy in Lung Cancer
09:30 - 09:30 | Author(s): R. Shavit
- Abstract
Loading... -
+
P2.04-048 - Analysis of Gene Expression in the Re-Replication Pathway and Selective Blockade with Checkpoint Inhibitors as a Therapeutic Option in NSCLC
09:30 - 09:30 | Author(s): D. Morales-Espinosa
- Abstract
Loading... -
+
P2.04-049 - Efficacy of Focal Adhesion Kinase (FAK) Inhibition in RAS Mutant and EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)
09:30 - 09:30 | Author(s): H. Zhang
- Abstract
Loading... -
+
P2.04-050 - Basaloid Squamous Cell Cancers Arising from the Lung: Next Generation Sequencing Reveals PTCH1 Mutations in the Hedgehog Pathway
09:30 - 09:30 | Author(s): B.T. Li
- Abstract
Loading... -
+
P2.04-051 - The Pluripotency Factor Musashi-2 Is a Potential Target for Lung Cancer Therapy
09:30 - 09:30 | Author(s): M. Zhang
- Abstract
Loading... -
+
P2.04-052 - Targeting Oncogenic Eukaryotic Protein Translation in Thoracic Malignancies with Small-Molecule Inhibitors
09:30 - 09:30 | Author(s): Z. Ahmad
- Abstract
Loading... -
+
P2.04-053 - Patient-Derived Xenograft Studies Suggest FGFR1 Amplification Is Insufficient to Predict Response to FGFR Inhibitors in Lung SqCC
09:30 - 09:30 | Author(s): S. Sakashita
- Abstract
Loading... -
+
P2.04-054 - Targeting DNA Methylation in Chromatin
09:30 - 09:30 | Author(s): W. Han
- Abstract
Loading... -
+
P2.04-055 - Anti-Glut-1 Antibody as a Novel Therapeutic Modality against Breast and Lung Cancers
09:30 - 09:30 | Author(s): V. Vaghani
- Abstract
Loading... -
+
P2.04-056 - Analysis of EGFRvIII, PIK3CA, and DDR2 Mutations in Chinese Lung Squamous Cell Carcinoma Patients
09:30 - 09:30 | Author(s): M. Li
- Abstract
Loading... -
+
P2.04-057 - Targeting PIM Kinase in NSCLC
09:30 - 09:30 | Author(s): K. Gately
- Abstract
Loading... -
+
P2.04-058 - Neutrophil-Lymphocyte Ratio (NLR) as a Prognostic Marker in Locally Advanced Non-Small Cell Lung Cancer (LANSCLC)
09:30 - 09:30 | Author(s): K.A. Schrenk
- Abstract
Loading... -
+
P2.04-059 - Structural and Functional Characterization of the Hemolymphangiogenic Microenvironment in Lung Cancer
09:30 - 09:30 | Author(s): F. Quaini
- Abstract
Loading... -
+
P2.04-060 - Analysis of Lung Microbiome From Patients Undergoing Bronchoscopy
09:30 - 09:30 | Author(s): G.J. Weiss
- Abstract
Loading... -
+
P2.04-061 - Tumor-Associated Fibroblasts Increased Density in Non-Small Cell Lung Cancer Is Mediated by Microenvironment Through β1/FAK Signaling
09:30 - 09:30 | Author(s): N. Reguart
- Abstract
Loading... -
+
P2.04-062 - Temporal Programming of Murine Pulmonary Macrophages in N-Nitroso-Tris-(2-Chloroethyl) Urea (NTCU)-Induced Squamous Dysplasia
09:30 - 09:30 | Author(s): L.D. Dwyer-Nield
- Abstract
Loading... -
+
P2.04-063 - Secretome of BM Mesenchymal Stem Cells: An Emerging Player in NSCLC Progression
09:30 - 09:30 | Author(s): O. Attar-Schneider
- Abstract
Loading... -
+
P2.04-064 - Microenvironmental Factor of Primary Lung Adenocarcinoma Which Predicts the Effectiveness of Chemotherapy in Patients with Recurrences
09:30 - 09:30 | Author(s): H. Koriyama
- Abstract
Loading... -
+
P2.04-065 - Distant Bystander Effect of REIC/Dkk-3 Gene Therapy through Immune System Stimulation in a Murine Model of Thoracic Malignancies
09:30 - 09:30 | Author(s): K. Suzawa
- Abstract
Loading... -
+
P2.04-066 - Programmed Cell Death Ligand 1 (PD-L1) Overexpression and Low Immune Infiltrate Score Correlate with Poor Outcome in Lung Adenocarcinoma
09:30 - 09:30 | Author(s): E.R. Parra Cuentas
- Abstract
Loading... -
+
P2.04-067 - Clinical Characteristics Associated with PDL1 Positive Status in Resected NSCLC
09:30 - 09:30 | Author(s): G. Geller
- Abstract
Loading... -
+
P2.04-068 - PD-L1 Expression in Tumor Infiltrating Immune Cells Determined by Digital Imaging Is Associated with Poor Survival in NSCLC Patients
09:30 - 09:30 | Author(s): B.G. Reyna Asuncion
- Abstract
Loading... -
+
P2.04-069 - Characteristics and PD-1/PD-L1 Expression of Periphera CD4+CD25+CD127low Treg Cells in Lung Cancer
09:30 - 09:30 | Author(s): X. Pan
- Abstract
Loading... -
+
P2.04-070 - Immunological Characterization of PD-L1-Positive Non-Small Cell Lung Cancer Cells
09:30 - 09:30 | Author(s): T. Igarashi
- Abstract
Loading... -
+
P2.04-071 - PD-L1 Expression Is Not Associated with Disease-Free Survival in NSCLC Patients Who Underwent Radical Resection
09:30 - 09:30 | Author(s): W. Liang
- Abstract
Loading... -
+
P2.04-072 - Immunohistochemical PDL1 Expression and Clinicopathological Characteristics in 541 Surgically Resected Non-Small Cell Lung Cancers
09:30 - 09:30 | Author(s): S. Mori
- Abstract
Loading... -
+
P2.04-073 - PD-L1 Expression Is Induced by MET in an Erlotinib-Resistant Cell Line with MET Amplification
09:30 - 09:30 | Author(s): C. Demuth
- Abstract
Loading... -
+
P2.04-074 - PD-L1 Gene Expression and Total Cell-Free RNA Measured in Blood Positively Differentiate Healthy Individuals from Metastatic NSCLC Patients
09:30 - 09:30 | Author(s): K. Danenberg
- Abstract
Loading... -
+
P2.04-075 - Network Analysis of Anti-CTLA4-Induced Regressing Tumours Identifies Novel Synergistic Drug Combinations
09:30 - 09:30 | Author(s): W.J. Lesterhuis
- Abstract
Loading... -
+
P2.04-076 - Dynamics of Soluble PD-1 during Treatment with EGFR-TKI in Advanced NSCLC Patients
09:30 - 09:30 | Author(s): S.F. Sorensen
- Abstract
Loading... -
+
P2.04-077 - PDL1 Expression in Metastatic Non-Small Cell Lung Cancer Patients from Colombia (CLICaP)
09:30 - 09:30 | Author(s): A.F. Cardona
- Abstract
Loading... -
+
P2.04-078 - Functional Characterization of NK Cells in Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): O. Arrieta Rodriguez
- Abstract
Loading... -
+
P2.04-079 - Targeting Antigen Presentation by Tumor Infiltrating B Cells to CD4 T Cells in Non-Small Cell Lung Cancer Patient Tumors
09:30 - 09:30 | Author(s): T.C. Bruno
- Abstract
Loading... -
+
P2.04-080 - Novel Biomarkers for Non Small Cell Lung Cancer (NSCLC)
09:30 - 09:30 | Author(s): L. Tijani
- Abstract
Loading... -
+
P2.04-081 - The Role of B7-H4–Expressing Macrophage in Malignant Pleural Effusion
09:30 - 09:30 | Author(s): J.A. Huang
- Abstract
Loading... -
+
P2.04-082 - Diagnostic Value of Survivin-Expressing Circulating Tumor Cells in Patients with Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): M. Kim
- Abstract
Loading... -
+
P2.04-083 - Influence of Surgery on EGFR Mutation Abundance among Patients with Early-Stage Non–Small-Cell Lung Cancer
09:30 - 09:30 | Author(s): C. Yang
- Abstract
Loading... -
+
P2.04-084 - Next-Generation Sequencing with Digital Droplet PCR for Circulating Tumor DNA Quantification in Non-Small-Cell Lung Cancer Patients
09:30 - 09:30 | Author(s): N.P. Pécuchet
- Abstract
Loading... -
+
P2.04-085 - A Comparative Analysis of Cancer Hotspot Mutation Profiles in Circulating Tumour Cells, Circulating Tumour DNA and Matched Primary Lung Tumour
09:30 - 09:30 | Author(s): M. Leung
- Abstract
Loading... -
+
P2.04-086 - An Effective In Vivo Liquid Biopsy Tool for High-Yield Isolation of Circulating Tumor Cells
09:30 - 09:30 | Author(s): K. Luecke
- Abstract
Loading... -
+
P2.04-087 - Detection of Mutations from Peripheral Blood in Patients with Non-Small Cell Lung Cancer with Fast Turn-Around
09:30 - 09:30 | Author(s): K. Danenberg
- Abstract
Loading... -
+
P2.04-088 - Surrogate or Not: The Role for Cell Free Circulating DNA in Detecting EGFR Mutations Present in Tumor Tissue
09:30 - 09:30 | Author(s): S. Das
- Abstract
Loading... -
+
P2.04-089 - Detection of Epidermal Growth Factor Receptor (EGFR) Mutations in Circulating Tumor DNA During EGFR-Tyrosine Kinase Inhibitor Treatment
09:30 - 09:30 | Author(s): I. Oh
- Abstract
Loading... -
+
P2.04-090 - Changes in Circulating Epidermal Growth Factor Receptor (EGFR) during Radiotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients
09:30 - 09:30 | Author(s): P. Ye
- Abstract
Loading... -
+
P2.04-091 - Digital PCR Analysis of Plasma Cell-Free DNA as a Noninvasive Detection of the Drug Resistance Mechanisms in EGFR Mutant NSCLC
09:30 - 09:30 | Author(s): H. Ishii
- Abstract
Loading... -
+
P2.04-092 - Sequencing of Actionable EGFR Mutations from PtDNA in NSCLC: A Feasibility Study of Non-Invasive Analysis of Sensitivity to TKI
09:30 - 09:30 | Author(s): S. Tarasevych
- Abstract
Loading... -
+
P2.04-093 - Assessment of Clinical Applications of Circulating Tumor DNA in Lung Cancer Using an Enhanced TAm-Seq Platform
09:30 - 09:30 | Author(s): D. Gale
- Abstract
Loading... -
+
P2.04-094 - Exosomal MiRNA Analysis of Non-Small Cell Lung Cancer (NSCLC) Liquid Biopsies. Mirror of the Disease Status?: Proof of Concept Study
09:30 - 09:30 | Author(s): M. Giallombardo
- Abstract
Loading... -
+
P2.04-095 - Detection of Mutations in Tumor and Blood Samples from Lung Adenocarcinoma Patients Using Two Different Techniques
09:30 - 09:30 | Author(s): J.M. Clavero
- Abstract
Loading... -
+
P2.04-096 - Liquid Biopsies in Patients with EGFR Mutated Non-Small Cell Lung Cancer Undergoing Curative Treatment
09:30 - 09:30 | Author(s): E.B. Hansen
- Abstract
Loading... -
+
P2.04-097 - Vinorelbine Resistance in Lung Cancer; Role of Focal Adhesion Signaling Pathways
09:30 - 09:30 | Author(s): T. Nakanishi
- Abstract
Loading... -
+
P2.04-098 - Acquired Resistance to Anti-VEGF Therapy in Non-Small Cell Lung Cancer Is Not Associated with Angiogenic Compensation
09:30 - 09:30 | Author(s): R.E. Frink
- Abstract
Loading... -
+
P2.04-099 - Differential Regulation of DNA Repair Genes in Cisplatin Resistant Non-Small Cell Lung Cancer Cells
09:30 - 09:30 | Author(s): Y. He
- Abstract
Loading... -
+
P2.04-100 - Platin-Induced ATM Activation in Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): J. Moore
- Abstract
Loading... -
+
P2.04-101 - Ganetespib Resistance in KRAS Mutant NSCLC Is Mediated through Reactivation of the RAF/MEK/ERK and PI3K/MTOR Pathways
09:30 - 09:30 | Author(s): S. Chatterjee
- Abstract
Loading... -
+
P2.04-102 - Targeting Inflammatory Mediators to Overcome Intrinsic and Acquired Cisplatin Resistance in Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): A. Baird
- Abstract
Loading... -
+
P2.04-103 - A Goodpasture Antigen-Binding Protein Kinase Inhibitor to Treat Drug-Resistant Metastatic Lung Cancer
09:30 - 09:30 | Author(s): J. Saus
- Abstract
Loading... -
+
P2.04-104 - Regulating the Response to Cisplatin in Lung Cancer Cells through the Transcription Factor TCF4: A New Potential Role for Wnt Signaling
09:30 - 09:30 | Author(s): J. De Castro
- Abstract
Loading... -
+
P2.04-105 - PARP Inhibition Sensitises ATM Deficient NSCLC Cells to Cisplatin Treatment
09:30 - 09:30 | Author(s): A.A. Elegbede
- Abstract
Loading... -
+
P2.04-106 - Expression of AEG-1 Associated with Increase of TS Contributes to Chemoresistance of Pemetrexed in Lung Adenocarcinoma
09:30 - 09:30 | Author(s): C. Chen
- Abstract
Loading... -
+
P2.04-107 - Cofilin-1 as a Biomarker for Non-Small Cell Lung Cancer and a Potential Predictor to Platinum-Based Chemotherapy Resistance
09:30 - 09:30 | Author(s): J. Cé Coelho
- Abstract
Loading... -
+
P2.04-108 - The Role of miR-30c-2* in Clinical Outcome and Drug Resistance in HPV-Infected Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): Y. Cheng
- Abstract
Loading... -
+
P2.04-109 - Epithelial-To-Mesenchymal Transition (EMT) and Acquired Resistance to PI3K-mTOR Inhibition in NSCLC
09:30 - 09:30 | Author(s): K. Gately
- Abstract
Loading...
first
prev
